Why Organovo’s Latest Publication Matters

Publishing clinical data in a scientific journal might not usually be a big deal for most companies, but it could be for this 3D bioprinting pioneer.

At first glance, the publication from Organovo’s and Roche’s research doesn’t seem like such a big deal. For Roche, it isn’t. But for Organovo, the PLOS One paper represents another key step toward building a still relatively new market for 3D bioprinted human tissues.



Bioprinting Living Tissue For Functional Implants

From ‘bioficial’ 3D printed thyroid implants to a functional 3D printed eardrum, it seems that bioprinting takes a progressive step forward on a constant basis.

One research team based out of the Wake Forest Institute for Regenerative Medicine, led by Dr. Anthony Atala, has just succeeded in creating what could be one of the biggest breakthroughs in bioprinting thus far, a 3D printer capable of generating functional replacement tissue.



3D Bioprinting – Complete Change of Paradigm.

The possibilities offered by IBEC’s 3D bioprinter are endless. In the field of personalized medicine 3D bioprinter has the potential to reconstruct organ replicas – again, made with a patient’s own cells – for the functional testing of different treatments. Not only that, but 3D bioprinting could also be used to print small pieces of organs for applications in industrial processes, such as skin for the quality control of dermatological products.